Durvalumab news

All news on Durvalumab (also known as Imfinzi): plants, production capacities, investments and involved companies.

29 May 2026

Merck: FDA Grants Breakthrough Designation to Calderasib (MK‑1084) for First‑Line KRAS G12C‑Mutant Metastatic NSCLC

Supports calderasib plus pembrolizumab in PD‑L1 ≥1% newly diagnosed metastatic KRAS G12C NSCLC; positive Phase 1 KANDLELIT‑001 data; multiple Phase 3 trials planned; developed with Taiho/Astex

Who will be producing Durvalumab in the future?

Find out with chemXplore Alpha

Learn more